Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain EXEL message board posts where the ticker symbol EXEL has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest EXEL SEC Filings

Filings Format Description Filing Date File/Film Number
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0000215457-18-006117 (34 Act)  Size: 13 KB
2018-10-10 005-59687
181116259
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000939767-18-000210 Size: 7 KB
2018-10-03
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000939767-18-000209 Size: 11 KB
2018-10-03
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000939767-18-000208 Size: 10 KB
2018-10-03
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000939767-18-000204 Size: 7 KB
2018-09-26
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000939767-18-000202 Size: 5 KB
2018-09-12
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000939767-18-000201 Size: 5 KB
2018-09-12
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000939767-18-000200 Size: 5 KB
2018-09-12
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000939767-18-000199 Size: 5 KB
2018-09-12
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000939767-18-000198 Size: 5 KB
2018-09-12
More EXEL SEC Filings


Related news from
Thu, 11 Oct 2018
19:31:30 +0000
Tech and biotech on collision course, squeezed by the Peninsula's limited space
The rapidly growing sectors have been gobbling up workers and office space in San Mateo County. Now they are running into each other's growth ambitions
Mon, 08 Oct 2018
22:05:00 +0000
Cabozantinib to Be Featured in 13 Presentations at ESMO 2018 Congress
– Presentations to include results from the dose escalation stage of phase 1b COSMIC-021 study of cabozantinib in combination with atezolizumab in previously untreated advanced ren
Mon, 08 Oct 2018
18:34:17 +0000
Analysts Are Mostly Positive on Portola Pharmaceuticals
Portola Pharmaceuticals (PTLA) is focused on the development and commercialization of novel therapies with a special focus on thrombosis and hematologic diseases. Portola Pharmaceuticals currently has two FDA-approved drugs, Andexxa and Bevyxxa. Portola Pharmaceuticals is advancing its investigational drug, cerdulatinib, which is a Syk/JAK inhibitor.
Mon, 08 Oct 2018
14:10:02 +0000
Why the Earnings Surprise Streak Could Continue for Exelixis (EXEL)
Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Mon, 08 Oct 2018
12:06:16 +0000
See what the IHS Markit Score report has to say about Exelixis Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
Mon, 08 Oct 2018
12:00:00 +0000
Exelixis Initiates Phase 3 Pivotal Trial (COSMIC-311) of Cabozantinib in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed after Prior VEGFR-Targeted Therapy
– Thyroid cancer is the most rapidly increasing cancer in the U.S., with incidence tripling over the past 30 years –
Sun, 07 Oct 2018
17:00:00 +0000
3 Small Biotech Stocks to Watch in the Fourth Quarter
The S&P 500 had a good summer. The widely followed index rose more than 7% in the third quarter. It was the best quarterly performance for the S&P 500 since 2013. Profits among S&P 500 companies grew some 25% year over year in the first half of 2018 bolstered by robust domestic economic activity and a big drop in the corporate income tax rate.
Fri, 05 Oct 2018
15:00:00 +0000
Liver Cancers Rising - Stocks to Watch
HENDERSON, NV / ACCESSWIRE / October 5, 2018 / Liver cancer incidence has more than tripled since 1980. Liver cancer death rates have increased by almost 3% per year since 2000. More than 700,000 people ...
Wed, 03 Oct 2018
23:33:00 +0000
Top 5 Biotech Stocks for 2018
Many biotechnology products do not produce the desired results consistently, while others fail to gain acceptance in the marketplace. Given Celgene's solid long-term track record, the lackluster year-to-date performance may represent a buying opportunity.
Wed, 03 Oct 2018
19:37:41 +0000
How Did Exelixis Inc’s (NASDAQ:EXEL) 42% ROE Fare Against The Industry?
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will work through how we can use Return<div><a class="permalink" href="https://simplywall.st/news/yahoo-post/how-did-exelixis-incs-nasdaqexel-42-roe-fare-against-the-industry/">Read More...</a></div>
Wed, 03 Oct 2018
12:21:00 +0000
3 Top Mid-Cap Stocks to Buy in October
These high-growth mid-cap stocks are just what the doctor ordered.
Tue, 25 Sep 2018
20:05:00 +0000
Exelixis to Present at the Cantor Fitzgerald Global Healthcare Conference on October 2, 2018
— Presentation to be webcast on www.exelixis.com —
Mon, 24 Sep 2018
20:49:08 +0000
Exelixis, Ipsen Receive Positive CHMP Opinion for Cabometyx
Exelixis, Inc. (EXEL) and partner Ipsen get a positive opinion from the CHMP for Cabometyx tablets as a monotherapy for the second-line treatment of hepatocellular carcinoma in adults.
Sun, 23 Sep 2018
10:33:00 +0000
3 Top Biotech Stocks to Buy Right Now
These biotech stocks are profitable and poised to deliver nice gains for patient investors.
Fri, 21 Sep 2018
12:51:38 +0000
The Daily Biotech Pulse: Exelixis Liver Cancer Drug On Track For European Approval, Medtronic Goes Shopping, Opiant Snags BARDA Funding
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 20.) Abbott Laboratories (NYSE: ABT ) Acceleron ...
Fri, 21 Sep 2018
05:32:00 +0000
Exelixis’ Partner Ipsen Announces Positive CHMP Opinion for CABOMETYX® (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma
– In the phase 3 pivotal CELESTIAL trial, CABOMETYX demonstrated a statistically significant and clinically meaningful overall survival benefit –
Thu, 20 Sep 2018
20:42:08 +0000
Exelixis' Partner Ipsen Gets Approval for Cabometyx in Canada
Exelixis (EXEL) and partner Ipsen Biopharmaceuticals Canada gain approval for Cabometyx from Health Canada for the treatment of advanced renal cell carcinoma in adult patients.
Wed, 19 Sep 2018
18:38:48 +0000
7 Biotech Stocks to Buy Now
Now that the biotechnology sector is well on its way to bouncing back after bottoming in May 2018, investors may feel like they missed out. The fears that previously plagued biotech stocks are no longer as big a threat. The government is no longer putting companies hiking drug price in their cross-hairs, at least not for now. This favorable environment should help biotech firms carry out their plans for the rest of the year.
Wed, 19 Sep 2018
11:32:00 +0000
Exelixis’ Partner Ipsen Announces Health Canada’s Approval of CABOMETYX® (cabozantinib) Tablets for the Treatment of Adults with Previously Treated Advanced Renal Cell Carcinoma
– Approval based on the improvement in overall survival, progression-free survival and objective response rate for CABOMETYX versus everolimus in the phase 3 pivotal METEOR trial –



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "At VF I have met some of the greatest givers from all walks of life and from all parts of the world. I thank each of them for sharing part of their life and knowledge with me." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards